AGTR1 and susceptibility to pneumonia measurement: The development of cCHP NG incorporated with AT1R partial peptide conjugated to PspA (AT1R–PspA) and cyclic diguanylate monophosphate (di-GMP) as the adjuvant was used as a novel nasal vaccine against hypertension and pneumonia [149].